Cartesian Growth II Equity Warrant Exp 12 July 2028 Warrant

0.1362

0.0000

Volume:- -

Turnover:- -

Market Cap:- -

PE:- -

High:0.1362

Open:0.1362

Low:0.1362

Close:0.1362

52wk High:0.2300

52wk Low:0.0501

Shares:- -

Float Shares:- -

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

GlobeNewswire

·

Jul 17, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RENEW"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RENEW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RENEW\",,,,,undefined,":{"symbol":"RENEW","market":"US","secType":"STK","nameCN":"Cartesian Growth II Equity Warrant Exp 12 July 2028 Warrant","latestPrice":0.1362,"timestamp":1770411600000,"preClose":0.1362,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"02-06 16:00:00 EST","open":0.1362,"high":0.1362,"low":0.1362,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.1362,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RENEW\",,,,,undefined,":{"symbol":"RENEW","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0.1362,"amplitude":0,"preClose":0.1362,"low":0.1362,"week52Low":0.0501,"pbRate":"--","week52High":0.23,"institutionHeld":0,"latestPrice":0.1362,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0.1362,"prevYearClose":0.1362,"prevWeekClose":0.1362,"prevMonthClose":0.1362,"prevQuarterClose":0.1362,"fiveDayClose":0.1362,"twentyDayClose":0.1362,"sixtyDayClose":0.1362},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RENEW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"RENEW","reason":null,"defaultRemindTime":1747143000000,"announcedDate":"2025-05-12","type":"delisting","dateTimestamp":1747108800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RENEW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RENEW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RENEW\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552489947","title":"Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept","url":"https://stock-news.laohu8.com/highlight/detail?id=2552489947","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552489947?lang=en_us&edition=fundamental","pubTime":"2025-07-17 20:00","pubTimestamp":1752753600,"startTime":"0","endTime":"0","summary":"Milestone payment of $10 million triggered under the global license agreement with TakedaLEXINGTON, Mass., July  17, 2025  (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/17/3117170/0/en/Keros-Therapeutics-Announces-the-First-Patient-Dosing-in-the-Phase-3-RENEW-Clinical-Trial-of-Elritercept.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4539","BK4007","RENEW"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RENEW\",params:#limit:6,delay:false,,,undefined,":[]}}